If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
== Comparison with western philosophy == The concept of pratītyasamutpāda has also been compared to Western metaphysics, the study of reality. Schilbrack states that the doctrine of interdependent origination seems to fit the definition of a metaphysical teaching, by questioning whether there is anything at all. Hoffman disagrees, and asserts that pratītyasamutpāda should not be considered a metaphysical doctrine in the strictest sense, since it does not confirm nor deny specific entities or realities. The Hellenistic philosophy of Pyrrhonism parallels the Buddhist view of dependent origination, as it does in many other matters (see: similarities between Phyrrhonism and Buddhism). Aulus Gellius in Attic Nights describes how appearances are produced by relative interactions between mind and body and how there are no self-dependent things. The ancient Commentary on Plato's Theaetetus also defends a kind of relativism which states that nothing has its own intrinsic character. Jay L. Garfield states that Nagarjuna's Mulamadhyamikakarika uses the causal relation to understand the nature of reality, and of our relation to it. This attempt is similar to the use of causation by Hume, Kant, and Schopenhauer as they present their arguments. Nagarjuna uses causation to present his arguments on how one individualizes objects, orders one's experience of the world, and understands agency in the world.
Following the 2010 general election, negotiations led to David Cameron becoming prime minister as the head of a coalition government with the Liberal Democrats – the youngest holder of the office since the 1810s and the first coalition government in the country's history since World War II. His premiership was marked by the effects of the Great Recession; these involved a large deficit in government finances that his government sought to reduce through austerity measures. His administration passed the Health and Social Care Act and the Welfare Reform Act, which introduced large-scale changes to healthcare and welfare. He also enforced stricter immigration policies, introduced reforms to education and oversaw the 2012 London Olympics. The government privatised the Royal Mail and some other state assets, and legalised same-sex marriage in England and Wales. The Scottish National Party (SNP) became dominant in Scotland over the decade, with a referendum on Scottish independence held in 2014, returning a negative result. When the Conservatives secured an unexpected majority in the 2015 general election, Cameron remained as prime minister, this time leading a Conservative-only government. Meanwhile, the Conservative's coalition partner, the Liberal Democrats, saw their worst result in the party's modern history. Also in 2015, the Labour Party elected Jeremy Corbyn as its leader, who was considered the most left-wing leader of the party since Michael Foot (1980–83). Cameron's second ministry was dominated by the 2016 referendum on the UK's continuing membership of the EU.
== Reception == GameSpy named Garry's Mod the "PC Mod of the Year" in 2005. Craig Pearson of GamesRadar regarded it one of the best mods for cooperative gameplay in 2007. In 2017, Brendan Caldwell of Rock Paper Shotgun described the game as a "must-own sandbox game", while PCGamesN included it in its 2019 list of the "best sandbox games on PC".
== Medications == A variety of different sex-hormonal medications are used in feminizing hormone therapy for transgender women. These include estrogens to induce feminization and suppress testosterone levels; antiandrogens such as androgen receptor antagonists, antigonadotropins, GnRH modulators, and 5α-reductase inhibitors to further oppose the effects of androgens like testosterone; and progestogens for various possible though uncertain benefits. An estrogen in combination with an antiandrogen is the mainstay of feminizing hormone therapy for transgender women.
The board was reconstituted as Bromley Urban District Council in 1894 and the parish became Bromley Urban District. It formed part of the London Traffic Area from 1924 and the London Passenger Transport Area from 1933. In 1934, as part of a county review order, the borough was expanded by taking in 1,894 acres (766 hectares) from the disbanded Bromley Rural District; an area including parts of the parishes of Farnborough, Hayes, Keston and West Wickham. Bromley became part of the newly created Greater London in 1965, in the new London Borough of Bromley.
Sources: en.wikipedia.org
Chronic exposure to high level of nitrogen dioxide results in the allosteric inhibition of glutathione peroxidase and glutathione S-transferase, both of which are important enzymes found in the mucous membrane antioxidant defense system, that catalyse nucleophilic attack by reduced glutathione (GSH) on non-polar compounds that contain an electrophilic carbon and nitrogen. These inhibition mechanisms generates free radicals that causes peroxidation from the lipids in the mucous membrane leading to increased peroxidized erythrocyte lipids, a reaction that proceeds by a free radical chain reaction mechanism that result in oxidative stress. The oxidative stress on the mucous membrane causes the dissociation of the GSTp-JNK complex, oligomerization of GSTP and induction of the JNK pathway, resulting in apoptosis or inflammation of the bronchioles and pulmonary alveolus in mild cases. On migrating to the bloodstream, nitrogen dioxide poisoning results in an irreversible inhibition of the erythrocyte membrane acetylcholinesterase which may lead to muscular paralysis, convulsions, bronchoconstriction, the narrowing of the airways in the lungs (bronchi and bronchioles) and death by asphyxiation. It also causes a decrease in glucose-6-phosphate dehydrogenase which may results in glucose-6-phosphate dehydrogenase deficiency known as favism, a condition that predisposes to hemolysis (spontaneous destruction of red blood cells).
During the opening remarks of the talks, Xi said that "the whole world is watching our meeting. Currently, a transformation not seen in a century is accelerating across the globe, and the international situation is fluid and turbulent". He asked whether China and the US could escape the Thucydides trap and create a "new paradigm of relations". He congratulated the US on its 250th anniversary and added that China and the US "should be partners not rivals". He said that China and the US had agreed to establish a constructive China–US relationship of strategic stability, which he said included "benign stability with competition kept within bounds, a normalized stability in which differences are kept manageable, and an enduring stability in which peace can be expected". Xi said "the Taiwan question is the most important issue in China–US relations", adding "If it is handled properly, the bilateral relationship will enjoy overall stability. Otherwise, the two countries will have clashes and even conflicts, putting the entire relationship in great jeopardy". Xi said "'Taiwan independence' and cross-Strait peace are as irreconcilable as fire and water" while adding that peace in the Taiwan Strait is the "greatest common ground between China and the United States". Trump told Xi, "You're a great leader, sometimes people don't like me saying it, but I say it anyway". He said some people called this "the biggest summit ever" and that he looks forward "very much" to the discussions.
=== Conformational analysis === One of the primary methods for evaluating chemical stability and energetics is conformational analysis. Physical organic chemists use conformational analysis to evaluate the various types of strain present in a molecule to predict reaction products. Strain can be found in both acyclic and cyclic molecules, manifesting itself in diverse systems as torsional strain, allylic strain, ring strain, and syn-pentane strain. A-values provide a quantitative basis for predicting the conformation of a substituted cyclohexane, an important class of cyclic organic compounds whose reactivity is strongly guided by conformational effects. The A-value is the difference in the Gibbs' free energy between the axial and equatorial forms of substituted cyclohexane, and by adding together the A-values of various substituents it is possible to quantitatively predict the preferred conformation of a cyclohexane derivative. In addition to molecular stability, conformational analysis is used to predict reaction products. One commonly cited example of the use of conformational analysis is a bi-molecular elimination reaction (E2). This reaction proceeds most readily when the nucleophile attacks the species that is antiperiplanar to the leaving group. A molecular orbital analysis of this phenomenon suggest that this conformation provides the best overlap between the electrons in the R-H σ bonding orbital that is undergoing nucleophilic attack and the empty σ* antibonding orbital of the R-X bond that is being broken.
At the Villejuif Mental Hospital in November 1951, he and Montassut administered an intravenous dose to psychiatrist Cornelia Quarti, who was acting as a volunteer. Quarti noted the indifference but fainted upon getting up to go to the toilet, and so further testing was discontinued. (Orthostatic hypotension is a known side effect of chlorpromazine). Despite this, Laborit continued to push for testing in psychiatric patients during early 1952. Psychiatrists were reluctant initially, but on 19 January 1952, it was administered (alongside pethidine, pentothal and ECT) to Jacques Lh., a 24-year-old manic patient, who responded dramatically; he was discharged after three weeks, having received 855 mg of the drug in total. Pierre Deniker had heard about Laborit's work from his brother-in-law, who was a surgeon, and ordered chlorpromazine for a clinical trial at the Sainte-Anne Hospital Center in Paris where he was chief of the men's service. Together with the hospital director Jean Delay, they published their first clinical trial in 1952, in which they treated thirty-eight psychotic patients with daily injections of chlorpromazine without the use of other sedating agents. The response was dramatic; treatment with chlorpromazine went beyond simple sedation, with patients showing improvements in thinking and emotional behaviour. They also found that doses higher than those used by Laborit were required, giving patients 75–100 mg daily.
1919) 25 August – Kurt Gottfried, Austrian-born American physicist. 2 September – Frank Drake, American astronomer and astrophysicist (Drake equation), designer of the Arecibo message (b. 1930) 9 December – Ademar José Gevaerd, Brazilian ufologist (b. 1962)
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.